Migraine And Headache

Opioids Greatly Overused as Migraine Treatment, Study Finds

By August 17, 2017

For abortive medications, results showed that overall 18.9% of patients received all high quality abortive medication, 27% received some low quality abortive while 15.2% received opioids.

Investigational Migraine Drug Lasmiditan Effective in Phase 3 Study

By August 04, 2017

Results showed that a statistically significant number of those participants who received lasmiditan (in all doses) were pain-free at 2-hours post dosage compared to those who received placebo (the primary endpoint).

FDA Clears Non-Invasive Device to Treat Chronic Intractable Pain

By August 03, 2017

The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress.

CAM Use Among Migraine/Headache Sufferers Investigated

By August 02, 2017

The use of complementary and alternative medicine (CAM) specifically for the treatment of migraine and headache is "relatively low" in the U.S.

Aimovig for Migraine Prophylaxis Under FDA Review

By July 21, 2017

If approved by the FDA, Aimovig will be the first monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor specifically intended for migraine prophylaxis.

Drug-Free Cluster Headache Therapy Now Available

By July 18, 2017

The Food and Drug Administration (FDA) approved gammaCore in April after efficacy was demonstrated in two clinical trials involving over 200 patients with episodic cluster headaches (ACT1 and ACT2).

Is Telemedicine Viable for Long-Term Treatment of Headaches?

June 15, 2017

The study findings suggest that telemedicine may be valuable for headache sufferers who want to see a specialist without extra hassle or inconvenience, he said.

Non-Invasive Device Effective in Patients with Refractory Migraine

By June 12, 2017

Results showed that after three months, the use of Cefaly was associated with a statistically significant, albeit small, reduction in the number of headache days.

Galcanezumab Shown to Significantly Cut Monthly Migraine Days

By June 10, 2017

Patients in the galcanezumab group had statistically significant greater reduction in monthly migraine headache days with acute medication use compared to placebo.

A View to a Headache: Health Implications of Modern Urban Design

June 09, 2017

People who get migraines are particularly susceptible to the discomfort from repetitive patterns.

CGRP Targeted Drug Looks Promising for Migraine Prevention

By May 31, 2017

The HALO Clinical Research Program consists of two 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies that compared fremanezumab to placebo in adults with episodic and chronic migraine.

Biologic for Migraine Prevention Submitted to FDA

By May 18, 2017

Amgen announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for erenumab for the prevention of migraines.

Riboflavin May Be Effective for Some Migraine Sufferers

By May 16, 2017

The authors concluded that for adult prophylaxis, riboflavin "is well tolerated, inexpensive and most controlled clinical trials have shown modest reductions in migraine headache frequency."

Once-Monthly Biologic Looks Promising for Migraine Prophylaxis

By May 12, 2017

Lilly announced encouraging results from three Phase 3 studies of galcanezumab, EVOLVE-1, EVOLVE-2 and REGAIN, evaluating its efficacy and safety for the prevention of episodic and chronic migraine.

Erenumab for Chronic Migraine Prevention

By April 28, 2017

Tepper, Stewart et al. "Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomized, double-blind, placebo-controlled phase 2 trial". DOI: 10.1016/S1474-4422(17)30083-2.

Promising Results for Novel IV Migraine Therapy

By April 28, 2017

Results met the primary endpoint of a significant reduction in migraine days for the eptinezumab groups, as measured by 75% responder rates.

Novel, Non-Drug Therapy Gets FDA OK for Cluster Headaches

By April 18, 2017

The device is applied to the neck and transmits a mild electrical stimulation to the vagus nerve through the skin.

Weight and Migraine Occurrence: Is There a Link?

April 13, 2017

Obese people 27% more likely to have migraines; underweight 13% more likely.

Trokendi XR Gets Final FDA Approval for Migraine Prophylaxis

By April 06, 2017

In August 2016, the FDA granted tentative approval of the Company's one of two supplemental New Drug Applications (sNDAs). The final approval was contingent on the pediatric exclusivity of the drug in the adolescent population that expired March 28, 2017.

Qudexy XR Gains New Migraine Indication

By March 30, 2017

The FDA approved the sNDA's for Qudexy as prophylaxis of migraine headache in adults and children aged ≥12 years.

Migraine and Cervical Artery Dissection May Share Common Mechanism

March 08, 2017

Researchers found that compared to patients who had migraine with aura, those who had migraine without aura were 1.74 times more likely to have CEAD.

Review: Efficacy of Intranasal Drug Delivery in Emergency Settings

By March 07, 2017

In this study, researchers reviewed the evidence on the use of IN administration for several medications commonly used in the emergency department.

Nondrug Treatment Looks Promising for Migraines

March 02, 2017

Electrical stimulation can ease pain if started soon after symptoms begin

Antidepressants Often Prescribed for Unapproved Uses

February 23, 2017

Trazodone for insomnia most common off-label use for antidepressants

Positive Results Announced for Novel Microneedle Migraine Patch

By February 13, 2017

Zosano has announced positive results from their Phase 3 clinical trial of M207, the companies lead candidate for the treatment of migraine attacks.

Are Migraine Sufferers at Increased Risk for Stroke After Surgery?

January 12, 2017

Migraine sufferers may face a slightly higher risk of stroke after an operation, according to research published online January 10 in The BMJ.

Vitamin D Deficiency May Up Risk of Chronic Headache

By January 04, 2017

Findings further support the evidence associating low vitamin D with increased risk of chronic diseases.

Pediatric Migraines: Are Amitriptyline, Topiramate Effective Treatments?

October 28, 2016

For children and adolescents with migraine, amitriptyline and topiramate do not reduce headache frequency or headache-related disability more than placebo, according to a study published online in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the Child Neurology Society, held from October 26 to 29 in Vancouver, Canada.

Migraines and the Microbiome: What's the Link?

October 19, 2016

Migraneurs harbor significantly more microbes in their mouths and guts

Migraine Drug Dosage Strength No Longer Available

By October 17, 2016

Endo Pharmaceuticals has informed the Food and Drug Administration (FDA) of the discontinuation of Sumavel DosePro (sumatriptan injection), in the 4mg/0.5mL formulation.